Home Tags BCMA

Tag: BCMA

Advisory Committee Votes in Favor of Positive Benefit/Risk Profile for Belantamab...

The U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) has voted 12-0 in favor of positive benefit/risk profile for belantamab mafodotin...
Featured Image: Better times - ASCO | McCormick Place. Courtesy: © 2017 Fotolia. Used with permission.

ASCO 2020 – Advancing Antibody-drug Conjugates: Belantamab Mafodotin

Multiple myeloma is the third most common blood cancer and is generally considered treatable, but not curable. Research into new therapies is needed as...

GSK2857916 Demonstrates 60% Response Rate in Heavily Pre-treated Relapsed/Refractory Multiple Myeloma...

The investigational BCMA antibody-drug conjugate GSK2857916, also known as J6M0-mcMMAF, recently awarded Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and...